Gurnani M - Search Results

1

Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.

Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G. Nielsen LL, et al. Among authors: gurnani m. Clin Cancer Res. 1998 Apr;4(4):835-46. Clin Cancer Res. 1998. PMID: 9563876

2

Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs.

Nielsen LL, Gurnani M, Tyler RD. Nielsen LL, et al. Among authors: gurnani m. Cancer Res. 1992 Jul 1;52(13):3733-8. Cancer Res. 1992. PMID: 1617645

3

Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.

Nielsen LL, Gurnani M, Syed J, Dell J, Hartman B, Cartwright M, Johnson RC. Nielsen LL, et al. Among authors: gurnani m. Hum Gene Ther. 1998 Mar 20;9(5):681-94. doi: 10.1089/hum.1998.9.5-681. Hum Gene Ther. 1998. PMID: 9551616

4

Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.

Gurnani M, Lipari P, Dell J, Shi B, Nielsen LL. Gurnani M, et al. Cancer Chemother Pharmacol. 1999;44(2):143-51. doi: 10.1007/s002800050959. Cancer Chemother Pharmacol. 1999. PMID: 10412949

5

The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.

Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, DiGiacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL. Grace MJ, et al. Among authors: gurnani m. Am J Pathol. 1999 Dec;155(6):1869-78. doi: 10.1016/S0002-9440(10)65506-X. Am J Pathol. 1999. PMID: 10595917 Free PMC article.

6

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.

Nielsen LL, Shi B, Hajian G, Yaremko B, Lipari P, Ferrari E, Gurnani M, Malkowski M, Chen J, Bishop WR, Liu M. Nielsen LL, et al. Among authors: gurnani m. Cancer Res. 1999 Dec 1;59(23):5896-901. Cancer Res. 1999. PMID: 10606231

7

Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.

Nielsen LL, Gurnani M, Shi B, Terracina G, Johnson RC, Carroll J, Mathis JM, Hajian G. Nielsen LL, et al. Among authors: gurnani m. Cancer Res. 2000 Dec 15;60(24):7066-74. Cancer Res. 2000. PMID: 11156413

8

Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene.

Nielsen LL, Discafani CM, Gurnani M, Tyler RD. Nielsen LL, et al. Among authors: gurnani m. Cancer Res. 1991 Jul 15;51(14):3762-7. Cancer Res. 1991. PMID: 2065330

9

Development of a nude mouse model of ras-mediated neoplasia using WR21 cells from a transgenic mouse salivary tumor.

Nielsen LL, Gurnani M, Porter G, Trexler S, Emerson D, Tyler RD. Nielsen LL, et al. Among authors: gurnani m. In Vivo. 1994 May-Jun;8(3):295-302. In Vivo. 1994. PMID: 7803707

10

In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background.

Nielsen LL, Gurnani M, Catino JJ, Tyler RD. Nielsen LL, et al. Among authors: gurnani m. Anticancer Res. 1995 Mar-Apr;15(2):385-92. Anticancer Res. 1995. PMID: 7763010

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters